COPD | Control | p Value | |
n | 16 | 15 | |
Age, years | 65 (5.2) | 64 (5.7) | 0.83 |
Body mass index, kg/m2 | 26.5 (3.8) | 27.9 (3.8) | 0.33 |
Cigarette smoke exposure, pack years* | 36 (34–54) | 34 (28–46) | 0.58 |
Inhaled medications, number of subjects (%) | |||
Short acting beta agonist | 15 (94%) | ||
Anticholinergic | 10 (63%) | ||
Long acting beta agonist | 2 (12%) | ||
Inhaled corticosteroid | 1 (6%) | ||
ICS/LABA combination | 13 (81%) | ||
Postbronchodilator spirometry, % | |||
FEV1 % predicted | 47.8 (18.5) | 102.1 (10.2) | <0.001 |
FVC % predicted | 87.0 (13.9) | 100.9 (11.1) | 0.005 |
FEV1:FVC | 41.6 (11.8) | 79.2 (5.6) | <0.001 |
Emphysema severity* | |||
%LAA-950 | 26.3 (10.3–42.4) | 2.5 (1.1–3.8) | <0.001 |
%LAA-910 | 59.9 (43.4–64.9) | 26.3 (10.3–42.5) | 0.002 |
Aortic pulse wave velocity, m/s | 10.4 (2.0) | 8.5 (1.7) | 0.009 |
hsCRP, mg/l* | 2.1 (1.3–5.5) | 1.0 (0.5–35) | 0.04 |
Data presented as mean (SD) or n (%), except * median (IQR). Groups compared using Student t test except for * where groups compared with Mann–Whitney U test.
%LAA-910, percentage low attenuation voxels below −910 Hounsfield units; %LAA-950, percentage low attenuation voxels below −950 Hounsfield units; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; hsCRP, high-sensitivity C reactive protein; ICS, inhaled corticosteroid; LABA, long acting beta agonist.